A Phase 1, Nonrandomized, Open-Label Investigation of Subcutaneous Ramucirumab Administration in Participants With Advanced Solid Tumors
Latest Information Update: 01 Mar 2023
At a glance
- Drugs Ramucirumab (Primary)
- Indications Gastric cancer; Liver cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
- 31 Aug 2021 Status changed from active, no longer recruiting to discontinued (Study terminated due to a business decision).
- 06 May 2021 Status changed from recruiting to active, no longer recruiting.
- 24 Mar 2021 Planned number of patients changed from 24 to 30.